These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 20492875)

  • 21. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
    Griffiths CE; Strober BE; van de Kerkhof P; Ho V; Fidelus-Gort R; Yeilding N; Guzzo C; Xia Y; Zhou B; Li S; Dooley LT; Goldstein NH; Menter A;
    N Engl J Med; 2010 Jan; 362(2):118-28. PubMed ID: 20071701
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Etanercept, a TNF antagonist for treatment for psoriatic arthritis and psoriasis.
    Mease PJ
    Skin Therapy Lett; 2003 Jan; 8(1):1-4. PubMed ID: 12728284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Intermittent use of etanercept in psoriasis].
    Herrera E; Alcaide AJ
    Actas Dermosifiliogr; 2010 May; 101 Suppl 1():18-25. PubMed ID: 20492876
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Initial experience with routine administration of etanercept in psoriasis.
    de Groot M; Appelman M; Spuls PI; de Rie MA; Bos JD
    Br J Dermatol; 2006 Oct; 155(4):808-14. PubMed ID: 16965432
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.
    Kalb RE; Blauvelt A; Sofen HL; Chevrier M; Amato D; Calabro S; Wang J; Schenkel B; Gottlieb AB
    J Drugs Dermatol; 2013 Aug; 12(8):874-80. PubMed ID: 23986160
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term response to etanercept monotherapy in moderate to severe psoriasis: assessment in daily practice by the maintenance of low values of PASI and BSA.
    Fernández-Torres RM; Paradela S; Fonseca E
    J Dermatolog Treat; 2014 Feb; 25(1):54-6. PubMed ID: 23210771
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Transition of classical systemic treatments to etanercept].
    Ferrándiz C; Carrascosa JM
    Actas Dermosifiliogr; 2010 May; 101 Suppl 1():45-9. PubMed ID: 20492880
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of etanercept for the treatment of psoriasis: an overview of the Italian clinical experience from the real-life setting and independent studies.
    Vena GA; Cassano N; Piaserico S; Conti A; Girolomoni G
    Immunopharmacol Immunotoxicol; 2012 Dec; 34(6):901-6. PubMed ID: 22686544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
    Van Lümig PP; Lecluse LL; Driessen RJ; Spuls PI; Boezeman JB; van de Kerkhof PC; De Jong EM
    Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Refractory psoriasis treatment with etanercept].
    Mahiques Santos L; Martínez-Menchón T; Sánchez Carazo JL; Pérez-Ferriols A; Soriano Navarro CJ; Fortea Baixauli JM
    Med Clin (Barc); 2005 Sep; 125(10):371-3. PubMed ID: 16185546
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Juvenile generalized pustular psoriasis treated with etanercept.
    Fialová J; Vojáčková N; Vaňousová D; Hercogová J
    Dermatol Ther; 2014; 27(2):105-8. PubMed ID: 24703268
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Etanercept combined with methotrexate for high-need psoriasis.
    Driessen RJ; van de Kerkhof PC; de Jong EM
    Br J Dermatol; 2008 Aug; 159(2):460-3. PubMed ID: 18547310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Etanercept: efficacy and safety.
    Jiménez-Puya R; Gómez-García F; Amorrich-Campos V; Moreno-Giménez JC
    J Eur Acad Dermatol Venereol; 2009 Apr; 23(4):402-5. PubMed ID: 19210697
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Etanercept: an overview of its role in the treatment of psoriasis.
    Galindo MP; Bartlett BL; Gewirtzman A; Mendoza N; Tremaine AM; Tyring SK
    Expert Opin Drug Metab Toxicol; 2008 Mar; 4(3):305-10. PubMed ID: 18363545
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of etanercept in psoriatic patients previously treated with infliximab.
    Pitarch G; Sánchez-Carazo JL; Mahiques L; Oliver V
    Dermatology; 2008; 216(4):312-6. PubMed ID: 18230978
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of etanercept in the dermatology setting. A review.
    Lebwohl MG
    Am J Clin Dermatol; 2005; 6(1):49-59. PubMed ID: 15675890
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation.
    Martyn-Simmons CL; Green L; Ash G; Groves RW; Smith CH; Barker JN
    J Eur Acad Dermatol Venereol; 2009 Dec; 23(12):1394-7. PubMed ID: 19573024
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence and variation of the body mass index in patients treated with etanercept for plaque-type psoriasis.
    Esposito M; Mazzotta A; Saraceno R; Schipani C; Chimenti S
    Int J Immunopathol Pharmacol; 2009; 22(1):219-25. PubMed ID: 19309569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Etanercept in psoriasis.
    Papp KA
    Expert Opin Pharmacother; 2004 Oct; 5(10):2139-46. PubMed ID: 15461549
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
    Griffiths CE; Reich K; Lebwohl M; van de Kerkhof P; Paul C; Menter A; Cameron GS; Erickson J; Zhang L; Secrest RJ; Ball S; Braun DK; Osuntokun OO; Heffernan MP; Nickoloff BJ; Papp K;
    Lancet; 2015 Aug; 386(9993):541-51. PubMed ID: 26072109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.